Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC
The 6-month progression-free survival rate for the combination therapy was 52.2%.
Previous Post
Echocardiographic Assessment Shows Promise as Risk Predictor in PAH
Next Post
Staying Current: Your Guide to August 2025 Oncology Research
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago